Policy / Pricing Trump backs psychedelics for mental health in new executive order Pharmaceutical TechnologyTrump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field. Policy / PricingNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: AZ is three for three with COPD hope tozorakimab Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
